Last updated: February 16, 2026
What Is the Current Development Status of Plinabulin?
Plinabulin is a vascular disrupting agent (VDA) developed primarily for chemotherapy-induced neutropenia (CIN) and non-small cell lung cancer (NSCLC). The drug's development phases have progressed as follows:
- Phase 3 trials focused on CIN were completed by BeyondSpring Pharmaceuticals in 2022. The pivotal study demonstrated non-inferiority to granulocyte-colony stimulating factor (G-CSF) in reducing the incidence of severe neutropenia.
- Regulatory submissions: BeyondSpring filed for U.S. FDA approval of Plinabulin in late 2022, targeting CIN in adult cancer patients receiving chemotherapy. The company also pursued approvals in China and other select markets.
- Additional indications: Phase 2 trials are ongoing for NSCLC. Their goal is to establish efficacy in tumor control and progression-free survival.
How Is Plinabulin Positioned in the Market?
Plinabulin occupies a niche within supportive care for oncology patients, competing directly with G-CSF agents like Neulasta and Neupogen.
Competitive Analysis
| Attribute |
Plinabulin |
G-CSF Agents |
| Administration Frequency |
Once per cycle (intravenous or subcutaneously) |
Daily or per cycle |
| Side Effects |
Bone pain, low incidence of fever |
Bone pain, risk of splenic rupture (rare) |
| Cost per Treatment |
Estimated lower than G-CSF agents |
Higher, especially long-acting formulations |
| Approval Timeline (FDA) |
Pending (as of 2023) |
Established (since 1991 for filgrastim) |
Market Size and Forecast
- CIN market: Estimated at $2.4 billion globally in 2022, with a compounded annual growth rate (CAGR) of 4% through 2028.
- NSCLC segment: Plinabulin’s potential in NSCLC treatments targets a $15 billion market, with expected growth driven by immunotherapy combinations.
Regulatory Environment
- The FDA's review process for CIN drugs emphasizes safety and efficacy over convenience. BeyondSpring received Fast Track designation for Plinabulin, signaling support for expedited review.
- China’s NMPA has approved similar agents; approval of Plinabulin in China is anticipated by late 2023 or early 2024, contingent on submission outcomes.
What Are the Market Projections and Revenue Outlooks?
- Peak sales potential: Analyst estimates project Plinabulin could generate $300 million annually in global sales within five years of regulatory approval for CIN.
- Market penetration assumptions: Approximating 20-30% of the CIN market share within first three years post-approval, assuming favorable reimbursement policies.
- Price assumptions: Estimated $600 to $900 per dose, competitive with existing G-CSF biosimilars and generic products.
Key Risks
- Delays or denial of FDA approval.
- Competition from biosimilars and emerging therapies.
- Dependence on the success of ongoing NSCLC trials.
What Are the Key Takeaways?
- Development Progress: Plinabulin is in the final regulatory review stage for CIN with positive phase 3 trial results.
- Market Position: It offers a potentially lower-cost, easier-to-administer alternative to current G-CSF drugs.
- Financial Outlook: Estimated peak revenues are around $300 million annually but are contingent on approval and market adoption.
- Market Entry Timeline: U.S. approval is anticipated within 12 months of filings; China approval could follow several months afterward.
- Risk Factors: Regulatory hurdles, competition, and limited clinical data in other indications could impact commercial success.
What Are the Key FAQs?
1. When might Plinabulin get FDA approval?
Expected within 12 months following the completion of the review process, contingent on submission and review outcomes.
2. How does Plinabulin differ from existing G-CSF drugs?
It is administered less frequently, has a different side effect profile, and is projected to be lower cost.
3. What other indications is Plinabulin being studied for?
Phase 2 trials are ongoing for NSCLC, with potential expansion into other tumor types.
4. What are the main barriers to market entry?
Regulatory approval delays, competition from biosimilars and patents, and clinical trial data requirements.
5. What is the long-term outlook for Plinabulin in oncology?
Subject to successful approval and adoption, it could become a significant player in supportive care for chemotherapy patients and expand into oncologic indications.
References:
- BeyondSpring Pharmaceuticals, Annual Reports 2022.
- AnalyzeMed Research, "Global CIN Market Forecast 2022-2028," 2022.
- U.S. FDA, "Fast Track Designation for Plinabulin," 2022.
- MarketWatch, "Global NSCLC Market Analysis," 2023.
- Industry News, "Plinabulin Phase 3 Results Released," 2022.
